

East[®]

Empower Assess Share Trust





🛯 🗞 💟 - 🗉

Design: Co

Streamline the Design, Simulation, and Monitoring of **Fixed and Adaptive Clinical Trials**



- Simultaneously compare and contrast power curves for several designs
- View plot data to create tabular displays of operating characteristics
- Customize charts for effective communication with team members

Succeed with East®

教育・日・秋島

Look #

Power vs. Treatment Effect (δ

2 0.3 0.4 0.5 Treatment Effect (δ)

Des1 — Des2 — Des3 — Des4

Successful studies begin with the right design. East is the industry standard for designing adequate and well-controlled clinical trials as per FDA and EMA guidance. Since 1994, East has reliably and continu-ously enabled drug and medical device trial sponsors of all sizes to optimize their trial planning and monitoring efforts.

8 8 8

≪ III 🖳 - S. 🎭 💾 X <mark>-</mark> & 🛗 = S

FinalDesig

🕼 Log 🛃 Input 👘 🕻

Hide Read-offs

ent Effect (δ)

🖖 🕛 🛍 🛍 🎷 Κ 🖋 🕤 🕤 🕤

Design Type: Superiority \checkmark Number of Looks: 5 \checkmark

Input Method: Individual Means V Test Statistic: Z

0.3, 0.35

0 Std. Deviation (σ):

 Diagna of the second second

n Control (µ_c):

Normal ~

Mean Treatment (µ,):

ters Roundary

0.025

Input Method: E(\delta) and SD(\delta) $\qquad \lor$

ID Design No. of Test Type Looks Type

0.8:0.9:0.05

mputed 💿

bility of Success) Computed

 bits
 rype
 a
 a

 5
 1-Sided
 0.025
 0.021
 0.802

 5
 1-Sided
 0.025
 0.021
 0.802

 5
 1-Sided
 0.025
 0.022
 0.85

 5
 1-Sided
 0.025
 0.022
 0.85

 5
 1-Sided
 0.025
 0.022
 0.85

Type I Error (α)

Sample Size (n

Allocation Ratio: 1 (n_t/n_c)

Prior Distribution for: 5

E(δ): 0.25 SD(δ): 1

🕓 🎂 X 🔬 🚔 🌯

3 M Des3 Superiority Des4 Superiority

Power:

About Cytel Architect[™]

A modern and fully verified platform, specifically built to support clinical study planning and analysis, Cytel Architect opens new possibilities for in¬novation in design software by providing:

- An intuitive user experience to make complex methods
- Powerful simulation capabilities and data exploration tools
- R and SAS integration for users to extend core capabilities
- · Customizable reporting tools to create documents with all the salient design operating characteristics
- A common integrated environment for all of Cytel's design packages: Compass, and East®

Empower

Play a more strategic role in your organization. East simplifies and automates study design and simulation, freeing more of your time to contribute in greater ways to the success of your trial or program.

0 38 38

Include Options

Profile • 📝 🌹

0.35 0.3,0.

0.35 0.3,0.35 0.35 0.3,0.35 Number of Looks

Description: Group sequential designs allow the investigator t

of efficacy, harm, and/or futility with

iding the closing date of the sti

te the thus far collected data

ook at the end of the study when

Any positive integer from 1 to 20 For MAMS designs, it can be any integer from 1 to 5.

Acceptable Range

Assess

Rapidly generate multiple fixed, group sequential, and adaptive designs. Easily evaluate the robustness of your design to critical assumptions by performing sensitivity analysis. Use the tables and graphs to compare the operating characteristics of different approaches.

Share

Communicate the merits of various trial design options to the proj¬ect team with the help of readily understood graphs, tables, and flex-ible reporting capabilities. Share design properties in real time with East Architect's powerful simulation capabilities.

Trust

Depend on East, knowing it has been fully verified and intensely tested. East-generated designs have been relied upon for 25 years in countless actual studies at all the major pharmaceutical, biotech companies, and the FDA.

	- =	-			
	Sample Size / Even 374	ts			
	Time to 374	Time	TimeOn Stud	Status	
	Events (Cont.)	21053	20.2302632	0	
	Time to 374 Events (Treat.) Time to 374 Total Events 29.936	52632	8.32236842	1	
		31579	6.74342105	1	
		73684	3.75	1	
		68421	5.95394737	1	
	Time to 374 Sample Size	2.5	4.93421053	1	
		78947	5	1	
	Input O Time	73684	9.30921053	1	
		52632	14.7039474	-1	
	 Sample Size / Events 	3.125	11.8421053	1	
	□ Sample Size	26316	17.368421	0	
30	Modify	60	0.0) c 02 04 04 64 2 Information Fraction		



- Make data driven predictions
- Predict enrollments and events at the planning as well as interim stage
- Provide time-sensitive recommendations in an on-going study

nts vs. Time – ONCO

vents (Treat.) - Total Events



Empower Assess Share

Trust

Key Features & Benefits

- Verified and extensively tested software, currently used at the FDA
- More clinical trial designs than any other platform
- Wide choice of traditional and group sequential designs, incorporating the latest statistical methodologies to design innovative adaptive trials
- Flexible options for survival designs
- Powerful customizable simulation engines for sensitivity analysis and prediction
- Convenient trial monitoring dashboard to analyze interim data and facilitate decision-making
- Customizable charts and tables
- to enhance communication with stakeholders
- Comprehensive user manual & help tools
- Industry-leading and responsive technical support

What's New?

Three new modules: MCPMOD, ENRICH, PROGRAM

- Design and analyze dose-finding studies using MCPMod methodology
- Simulate clinical trials with flexible adaptation options for population enrichment and strong control of type-1 error
- Simulate a sequence of oncology trials with flexible Go/ No-Go rules

Disable effica<mark>cy or futility boundaries at</mark> selected interim looks

Compute Bayesian probability of success and predictive power

Design and simulate survival studies accounting for stratification

Test multiple hypotheses using graphical methods

Fixed Sample Size & Group Sequential Designs for Superiority, Non Inferiority and Equivalence

Charts & Tables

Stopping Boundaries scales: Z, score, p-value, delta, delta/sigma Error Spending Average Sample Number Power vs. Sample Size Power vs. Treatment Effect Sample Size/Events vs. Time Study Duration vs. Accrual

Multiple Comparison Procedures

Dunnett's Single Step & Step Down Bonferroni & Weighted Bonferroni Sidak Holm's Step Down Hochberg's Step Up Fixed Sequence Fallback

Survival Design Options

Piecewise Hazards, Dropout, & Accrual Simulate Non-Proportional Hazards Fixed or Variable Follow-up Committed Accrual Duration or Subjects Stratified sampling and stratified logrank test

Major Enhancements to Existing Modules:

BASE

design trials with Super Superiority margin

SEQUENTIAL design group sequential trials for equivalence studies

SURVIVAL

Generate Go/No-Go based survival simulations with survival and binary intermediary endpoints

ADAPT/SURVADAPT

Conduct SSR(sample-size re-estimation) for Non-Inferiority design and flexible monitoring with Muller and Schafer

MAMS

Generate MAMS (multi-arm multi-stage) designs with Discrete endpoint and p-value combination approach, Survival endpoints as well as continuous endpoints

PREDICT predict events using Weibull distribution

ESCALATE *alternative method mTPI-2*

ENDPOINTS

simulate trials with mixed endpoints

Boundaries

Display boundaries on multiple scales (Z, score, delta, conditional power) Selectively apply efficacy and/or futility boundaries at each look

Families

Error Spending Functions (Lan-Demets[Pocock, O'Brien-Fleming], Gamma, Rho, Interpolated) Generalized Haybittle-Peto Wang-Tsiatis Pampallona-Tsiatis p-value

Conditional Power Delta/Sigma

Options

Unequal Spacing of Looks Boundaries at Selected Looks Non-Binding Futility Boundaries

Interim Monitoring Dashboard

Error Spending Function Conditional Power Adjusted p-value Adjusted Point Estimate Post-Hoc Power Repeated Confidence Intervals

> Request an Evaluation Today sales@cytel.com



www.cytel.com





East[®] version 6.5 continues Cytel's 20+ years tradition of reliable innovation in the design, monitoring and simulation of clinical trials.

Game-changing new features in Multiple Comparison Procedure - Modelling, Population Enrichment, and Program Design, address emerging and persistent challenges in modern drug development.

The European Medicines Agency (EMA) has qualified the Multiple Comparison Procedure – Modelling (MCP-Mod) approach as an efficient statistical methodology for design and analysis of phase II dose finding studies

under model uncertainty. East MCPMOD allows for the design and analysis of such studies for normal, binomial and count endpoints, with a variety of candidate models, dose selection criteria, and optimal allocations.





East ENRICH supports the simulation of clinical trial designs with adaptation options for population enrichment, while strongly controlling type-1 error



rate. It provides flexibility in defining the promising zone for sample size increase, and enrichment zone for subgroup selection.

East PROGRAM simulates a sequence of clinical trials within an oncology program. One can simulate a dose escalation trial

(3+3, mTPI, CRM, BLRM, from East ESCALATE) followed by a cohort expansion phase. Alternatively, one can simulate a single-arm Phase 2 trial followed by a twoarm Phase 3 two trial. Both alternatives allow for the incorporation of flexible Go/No-Go rules.



Other Enhancements:

BASE Super Superiority

MAMS Binomial multi-stage Survival p-value combination

SEQUENTIAL Equivalence Group Sequential

ADAPT/SURVADAPT SSR for Non-Inferiority designs

Contact us for a free trial sales@cytel.com

PREDICT Weibull distribution

ESCALATE mTPI-2

MEP Mixed endpoint type **a**MCP

MULTIARM

SEQUENTIAL

East

EXACT

Learn more at www.cytel.com

MAMS

ADAPT

SURVINA

East

East Modules

Fast[®] supports flexible configurations of Fourteen modules, allowing users to choose a variety of packages based on their unique design needs.

New Modules



ESCALATE

ENDPOINTS